Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.150
-0.040 (-1.83%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 226 employees as of December 31, 2025. The number of employees increased by 13 or 6.10% compared to the previous year.
Employees
226
Change (1Y)
13
Growth (1Y)
6.10%
Revenue / Employee
$233,381
Profits / Employee
-$29,221
Market Cap
173.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 226 | 13 | 6.10% | 226 | 0 |
| Dec 31, 2024 | 213 | 5 | 2.40% | 213 | 0 |
| Dec 31, 2023 | 208 | 11 | 5.58% | 208 | 0 |
| Dec 31, 2022 | 197 | -9 | -4.37% | 193 | 4 |
| Dec 31, 2021 | 206 | -1 | -0.48% | 202 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| ProQR Therapeutics | 187 |
| Cartesian Therapeutics | 75 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Corbus Pharmaceuticals Holdings | 36 |
| Achieve Life Sciences | 25 |
| Unicycive Therapeutics | 23 |
PLX News
- 9 days ago - Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance - Seeking Alpha
- 16 days ago - Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - PRNewsWire
- 23 days ago - Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - PRNewsWire
- 25 days ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - GlobeNewsWire
- 2 months ago - A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
- 2 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 2 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewsWire